Open access
Sep 2026
Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States.
Physician-reported outcomes show that ruxolitinib cream monotherapy substantially reduced the extent and severity of moderate AD, suggesting that it provides an effective topical treatment option in these specific populations.
Ji-Nan Liu, O. Howell, J. Piercy et al.
· Journal of dermatological tr... · 0 citations